Last reviewed · How we verify
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist is a Thrombopoietin Receptor Agonist Small molecule drug developed by The First Affiliated Hospital of Soochow University. It is currently in Phase 3 development for Thrombocytopenia. Also known as: Eltrombopag / Avatrombopag.
Thrombopoietin Receptor Agonists stimulate the thrombopoietin receptor to increase platelet production.
Thrombopoietin Receptor Agonists stimulate the thrombopoietin receptor to increase platelet production. Used for Thrombocytopenia.
At a glance
| Generic name | Thrombopoietin Receptor Agonist |
|---|---|
| Also known as | Eltrombopag / Avatrombopag |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Thrombopoietin Receptor Agonist |
| Target | Thrombopoietin Receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
By activating the thrombopoietin receptor, Thrombopoietin Receptor Agonists mimic the action of thrombopoietin, a hormone that regulates platelet production in the bone marrow. This leads to increased platelet production and, potentially, improved outcomes in conditions characterized by low platelet counts.
Approved indications
- Thrombocytopenia
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
- Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) (PHASE1)
- A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients (PHASE1)
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (PHASE2)
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (PHASE2)
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies (PHASE2)
- Romiplostim N01 for Platelet Recovery After Haploidentical HSCT (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thrombopoietin Receptor Agonist CI brief — competitive landscape report
- Thrombopoietin Receptor Agonist updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI
Frequently asked questions about Thrombopoietin Receptor Agonist
What is Thrombopoietin Receptor Agonist?
How does Thrombopoietin Receptor Agonist work?
What is Thrombopoietin Receptor Agonist used for?
Who makes Thrombopoietin Receptor Agonist?
Is Thrombopoietin Receptor Agonist also known as anything else?
What drug class is Thrombopoietin Receptor Agonist in?
What development phase is Thrombopoietin Receptor Agonist in?
What are the side effects of Thrombopoietin Receptor Agonist?
What does Thrombopoietin Receptor Agonist target?
Related
- Drug class: All Thrombopoietin Receptor Agonist drugs
- Target: All drugs targeting Thrombopoietin Receptor
- Manufacturer: The First Affiliated Hospital of Soochow University — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Thrombocytopenia
- Also known as: Eltrombopag / Avatrombopag
- Compare: Thrombopoietin Receptor Agonist vs similar drugs
- Pricing: Thrombopoietin Receptor Agonist cost, discount & access